Study guide
10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
Key Takeaways Explain This Topic AI
The pharmacotherapy workup is a six-step cycle: identify drug therapy problems, set goals, select therapy, implement, monitor, and follow up.
Drug therapy problems fall into four categories — indication, effectiveness, safety, and adherence — and each requires a structured recommendation.
A complete therapy recommendation specifies drug, dose, route, frequency, duration, monitoring parameters, and alternatives.
SOAP documentation organizes progress notes into Subjective, Objective, Assessment, and Plan, providing the legal and clinical record of decision making.
MTM consists of five core elements: medication therapy review, personal medication record, medication action plan, intervention/referral, and documentation/follow-up.
Last updated: July 2026
10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
Quick Answer: Sub-domain D closes the assessment loop. After you identify a drug therapy problem, you set measurable therapeutic goals, choose an evidence-based regimen, implement it with correct dose and route, build a monitoring plan, document in SOAP format, counsel the patient, and arrange follow-up. This six-step pharmacotherapy workup is the cognitive blueprint behind every MTM encounter.
The Pharmacotherapy Workup
The pharmacotherapy workup (Cipolle, Strand, Morley) is the standardized cognitive process pharmacists use to resolve drug therapy problems. It proceeds in six interdependent steps.
Step 1: Identify Drug Therapy Problems
Every patient encounter begins with a problem list. Drug therapy problems are grouped into four categories :
Indication — the patient needs a drug they are not taking (untreated condition), is taking a drug with no valid indication, or needs additional therapy.
Effectiveness — the drug is wrong for the condition, or the dose is too low to achieve the goal.
Safety — the patient is experiencing an adverse drug reaction, or the dose is too high.
Adherence — the patient is not taking the drug as prescribed for financial, behavioral, or access reasons.
A single patient often has multiple problems across categories. Listing them explicitly drives the rest of the workup.
Step 2: Goal Setting
Therapeutic goals must be measurable , patient-specific , and time-bound . For hypertension, the goal might be "BP < 130/80 mmHg within 4 weeks" (per ACC/AHA). For type 2 diabetes, "A1c < 7% within 3 months" unless the patient is elderly or hypoglycemia-prone, in which case < 8% may be safer. Align goals with the patient's values — a frail 90-year-old may prioritize fall prevention over tight glucose control.
Step 3: Therapy Selection
Select therapy that is evidence-based , patient-specific , and guideline-concordant . Apply the GRADE framework : high-quality evidence (randomized trials) with strong recommendations pushes the decision, but patient values and preferences can modify it. Account for comorbidities (avoid NSAIDs in CKD), renal/hepatic function (dose-adjust gabapentin by CrCl), age (start low and go slow in geriatrics), and pregnancy/lactation (refer to Hale's Medications and Mothers' Milk).
Step 4: Implementation
Specify drug, dose, route, frequency, duration . Example: "metformin 500 mg PO twice daily with meals, titrate to 1000 mg BID over 4 weeks, indefinite." The instruction "take as directed" is never acceptable.
Step 5: Monitoring Plan
A monitoring plan has three limbs:
Efficacy : primary endpoint (A1c, BP, lipid panel) and secondary endpoints (symptom relief, weight).
Safety : adverse drug reactions, drug-specific labs (LFTs for statins, potassium for ACE inhibitors, levels for vancomycin).
Tolerability : GI upset, dizziness, sedation — subjective symptoms that affect adherence.
Each parameter needs a timeline (e.g., recheck A1c in 3 months, BMP in 1 week).
Step 6: Follow-Up
Define when and how the patient will be reassessed. Adjust, escalate, or discontinue therapy based on the response. The cycle then restarts.
SOAP Note Documentation
Pharmacists document the workup in SOAP format, which is the legal record of clinical reasoning and the communication vehicle for the care team.
Section Content Example
S — Subjective Patient-reported information "I've had morning joint stiffness for 3 weeks. Tylenol helps a little."
O — Objective Measurable data: vitals, labs, med list BP 158/96, HR 82, SCr 1.1, current meds: lisinopril 10 mg daily
A — Assessment Clinical interpretation, drug therapy problems Hypertension uncontrolled on ACE inhibitor monotherapy; adherence confirmed by refill history.
P — Plan Drug, dose, route, frequency, duration, monitoring, education Increase lisinopril to 20 mg daily; add HCTZ 12.5 mg daily; recheck BP in 2 weeks; BMP in 1 month; counsel on salt restriction.
Components of a Therapy Recommendation
A complete recommendation answers all of the following:
- Drug : generic name, rationale, strength of recommendation
- Dose : mg, mg/kg, or weight-based
- Route : oral, IV, intranasal, transdermal
- Frequency : daily, BID, PRN with parameters
- Duration : number of days, indefinite, or stop criteria
- Monitoring : efficacy and safety parameters with timing
- Alternatives : what to do if the first-line fails or is contraindicated
Vague recommendations such as "start an antibiotic" lose credibility with prescribers and risk patient harm.
Patient-Specific Dose Adjustments
Renal dose adjustment uses Cockcroft-Gault for label-driven changes (e.g., gabapentin, levofloxacin, apixaban). Hepatic adjustment is less formulaic: use Child-Pugh classification (A, B, C) and drug-specific labeling — for example, voriconazole requires a standard load but half maintenance dose in mild-to-moderate hepatic impairment. Pediatric dosing is weight- or BSA-based (mg/kg or mg/m²). Geriatric dosing follows "start low, go slow" — initiate at 25–50% of the adult dose and titrate based on response and tolerability. Pregnancy and lactation require risk-benefit analysis using the FDA Pregnancy and Lactation Labeling Rule (PLLR), which replaced the old A/B/C/D/X categories.
Evidence-Based Decision Making
Guidelines (ADA, JNC-8/AHA, GINA, GOLD, IDSA) synthesize evidence but must be applied to the individual patient. The GRADE framework rates evidence quality (high, moderate, low, very low) and recommendation strength (strong or conditional/weak). A strong recommendation means most patients should receive the intervention; a conditional recommendation requires shared decision making. Patient values, cost, and access modulate every choice.
Patient Education and Counseling
Effective counseling uses the Indian Health Service three prime questions (or the teach-back method): What did your doctor tell you the medication is for? How did your doctor tell you to take it? What did your doctor tell you to expect? Education must cover:
- Purpose — what the drug does and why it matters
- Dosing — when to take, with or without food, what to do if a dose is missed
Administration technique — inhaler (MDI with spacer, DPI breath-actuated, soft-mist inhaler), injectable (insulin pen, autoinjector for epinephrine or biologics), transdermal patch (rotate sites), vaginal cream, suppository
- Side effects — common vs serious, what to do, when to call
- Interactions — drug-drug, drug-food (warfarin–vitamin K), drug-disease
- Storage — refrigeration, light protection, expiry
- Device Training Highlights
MDI : shake, exhale fully, seal lips, press + inhale slowly, hold breath 10 sec, wait 1 min between puffs; use a spacer to reduce oropharyngeal deposition.
DPI : load dose, exhale away from device, inhale rapidly and deeply, do not exhale into device (moisture ruins the powder).
Insulin pen : prime 2 units before first use, rotate injection sites (abdomen, thigh, arm), pinch skin, inject at 90°, hold 10 sec.
Autoinjector : outer thigh, hold 3–10 sec depending on device, massage site, call 911 (epinephrine).
Self-Management Education
Diabetes : carbohydrate counting (15 g = 1 carb serving), sick-day rules (continue insulin, check glucose every 4 h, drink fluids, call if vomiting or glucose > 240 with ketones), hypoglycemia rule of 15 (15 g fast carbohydrate, recheck in 15 min). Anticoagulation : dietary vitamin K consistency, bleeding signs (black stools, nosebleeds, excessive bruising), fall prevention, procedure holds. Asthma : trigger avoidance, action plan (green/yellow/red zones), rescue vs controller distinction.
Care Transitions and Collaborative Practice
Transitions of care are high-risk windows for medication errors. The pharmacist reconciles the admission, transfer, and discharge medication lists; provides discharge counseling; arranges follow-up (primary care, anticoagulation clinic, MTM); and communicates pending labs to the receiving team. Collaborative practice agreements (CPAs) authorize pharmacists to initiate, adjust, or discontinue drug therapy under a predefined protocol — common in anticoagulation, diabetes, and hypertension management.
Medication Therapy Management (MTM)
MTM is the CMS-defined service with five core elements :
Medication Therapy Review (MTR) — systematic review of all medications (prescription, OTC, herbal).
Personal Medication Record (PMR) — patient-friendly list of all medications including dose, route, frequency, indication.
Medication Action Plan (MAP) — patient-facing to-do list with action items and owner.
Intervention and/or Referral — pharmacist resolves problems or refers to prescriber.
Documentation and Follow-up — SOAP note, billing (CPT 99605/99606 for comprehensive MTM), and scheduled follow-up.
A Comprehensive Medication Review (CMR) is the cornerstone encounter: a real-time, interactive, patient-centered review of all medications. CMRs are required for Part D MTM programs and are increasingly delivered via telehealth.
- Pharmacotherapy Workup Flow [1. Identify drug therapy problems]
- |
- v
- [2. Set therapeutic goals]
- |
- v
- [3. Select evidence-based therapy]
- |
- v
- [4. Implement: drug, dose, route, frequency, duration]
- |
- v
- [5. Monitor: efficacy + safety + tolerability]
- |
- v
- [6. Follow-up and adjust] --> loops back to Step 1
This cycle is iterative: each follow-up generates new assessment data, new drug therapy problems, and new recommendations. The pharmacist's value is sustained across cycles rather than delivered as a single intervention.
SOAP Note Example — Hypertension Follow-Up
Section Content Pharmacist Contribution
S (Subjective) Patient reports taking lisinopril every morning, denies cough, headache, or swelling. Walks 30 min 3×/week. Diet includes restaurant meals 4×/week. Build rapport; verify adherence; probe side effects.
O (Objective) BP 158/96, HR 82, BMI 31, SCr 1.1, K 4.2, A1c 6.1. Refill history: 90-day fills on time for 6 months. Analyze labs, vitals, refill data.
A (Assessment) Stage 2 hypertension uncontrolled on ACE monotherapy. Adherence confirmed. Lifestyle modification partial. No ACE-induced cough or hyperkalemia. Identify drug therapy problem: effectiveness — dose too low.
P (Plan) Increase lisinopril to 20 mg daily. Add HCTZ 12.5 mg daily. Refer to dietitian for DASH counseling. Recheck BP in 2 weeks; BMP in 1 month. Document and notify prescriber. Complete recommendation with drug, dose, monitoring, education, follow-up.
This SOAP note illustrates how each section feeds the next: subjective context frames the objective data, the assessment integrates both into a drug-therapy problem statement, and the plan operationalizes the recommendation. Pharmacists should practice writing assessments as explicit problem statements ("uncontrolled hypertension on ACE monotherapy — effectiveness: dose too low") rather than restating the data, because the assessment is the cognitive step where clinical reasoning becomes visible and billable.